Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|domeglicant||treatment of diabetes|
|doncanatide||treatment of GI disorder; inflammatory bowel disease|
|pegmodglutide||treatment of diabetes and/or obesity|
|susquetide||reduce intensity and duration of tissue damage caused by inflammation cascade and mucositis, increase clearance of bacterial infection|
|tofeglicant||treatment of diabetes|
|fonadelpar||treatment of patients with moderate to severe corneal epithelial wounds|
|bulamuzumab||treatment of muscle wasting disorders|
|labetuzumab govitecan||treatment of cancer|
|landomuzumab||treatment of muscle wasting disorders|
|sunakinra||ocular surface inflammation|
|trevomumab||treatment of muscle atrophy due to orthopedic disuse and sarcopenia|